Skip to main content
Clinical Trials/NCT01420159
NCT01420159
Completed
Phase 3

A Randomised, Double Blind, Multi-centre, Placebo Controlled Study to Evaluate the Efficacy and Safety of Methoxyflurane (Penthrox) for the Treatment of Acute Pain in Patients Presenting to an Emergency Department With Minor Trauma

Medical Developments International Limited6 sites in 1 country300 target enrollmentAugust 2011

Overview

Phase
Phase 3
Intervention
Methoxyflurane
Conditions
Acute Pain Due to Trauma
Sponsor
Medical Developments International Limited
Enrollment
300
Locations
6
Primary Endpoint
VAS Score
Status
Completed
Last Updated
13 years ago

Overview

Brief Summary

This study investigates the treatment of acute pain, an unpleasant feeling caused by an injury. The overall purpose of the study is to gain more information that the pain relief medicine Penthrox(Methoxyflurane) administered using the Penthrox Inhaler(a distinctive green, whistle like object that you breathe through) is safe and works at relieving pain in patients aged 12 years and older who are admitted to a hospital Emergency Department with a minor injury (known as trauma).

Registry
clinicaltrials.gov
Start Date
August 2011
End Date
July 2012
Last Updated
13 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients 12 years of age or older who are able to give written informed consent or who are accompanied by a parent(s)/legal guardian able to provide written informed consent on their behalf.
  • Evidence of signed and dated informed consent document(s) indicating that the patient (and/or a parent/legal guardian) has been informed of all pertinent aspects of the study.
  • Pain Score ≥ 4 to ≤ 7 as measured using Numerical Rating Scale (NRS) at the time of admission, due to minor trauma.

Exclusion Criteria

  • Life-threatening condition requiring immediate admission in the Operating Room or Intensive Care Unit.
  • Presence of any other clinical condition(s) that may, in the opinion of the investigator, impact on the patient's ability to participate in the study, or on the study results, including history of head injury and/or altered consciousness.
  • Unable to provide written informed consent.
  • Known pregnancy or lactation
  • Acute intoxication with drugs or alcohol, based on the judgement of the attending physician.
  • Treatment with any analgesic agent within 5 hours prior to presentation to ED (except diclofenac sodium which is prohibited within 8 hours prior to presentation to ED).
  • Current ongoing use of analgesics for chronic pain.
  • Use of an investigational product within one month prior to presentation to ED.
  • Known personal or familial hypersensitivity to fluorinated anaesthetics.
  • Known personal or familial history of malignant hyperthermia.

Arms & Interventions

Methoxyflurane

Intervention: Methoxyflurane

Normal Saline

Intervention: Methoxyflurane

Outcomes

Primary Outcomes

VAS Score

Time Frame: Twenty Minutes

The difference between treatment and placebo on the VAS pain score

Secondary Outcomes

  • Time to pain relief(Up to a maximum of 6 hours)
  • Rescue Medication(Up to a maximum of 6 hours)
  • Responder analysis(Up to a maximum of 6 hours)
  • Safety Analysis(Up to 16 days)

Study Sites (6)

Loading locations...

Similar Trials